Vimarsana
Biggest News Aggregation in the World

Page 2 - Randomized Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Clinical Today - Breaking & Trending Today

Krill oil as a sustainable clinically proven omega-3 source - Vimarsana News

Krill oil as a sustainable clinically proven omega-3 source

As sustainability awareness grows and omega-3 demand rises, krill oil stands out as a sustainable and stable alternative.

Kaneka Ubiquinol supplement for healthy aging and antioxidant activity - Vimarsana News

Kaneka Ubiquinol supplement for healthy aging and antioxidant activity

Ubiquinol supplementation can be an effective way to promote healthy aging and protect the body from oxidative stress.

Navigating the Psychedelic Renaissance: Emerging Mental Health Therapies and the Pharmacist's Role - Vimarsana News

Navigating the Psychedelic Renaissance: Emerging Mental Health Therapies and the Pharmacist's Role

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Little Pills, Big Risks: The Untold Dangers of Referring to Low-Dose Aspirin as 'Baby Aspirin' - Vimarsana News

Little Pills, Big Risks: The Untold Dangers of Referring to Low-Dose Aspirin as 'Baby Aspirin'

Aspirin, known as acetylsalicylic acid, has been marketed in ways that have de-emphasized potential risks to children.

Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older - Vimarsana News

Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older

Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.